These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 38129674

  • 1. Pre-treatment bone turnover does not influence the level of the response to alendronate in postmenopausal osteoporosis at the bone tissue level.
    Chavassieux P, Roux JP, Chapurlat R.
    Osteoporos Int; 2024 Apr; 35(4):653-658. PubMed ID: 38129674
    [Abstract] [Full Text] [Related]

  • 2. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
    Stepan JJ, Burr DB, Li J, Ma YL, Petto H, Sipos A, Dobnig H, Fahrleitner-Pammer A, Michalská D, Pavo I.
    Osteoporos Int; 2010 Dec; 21(12):2027-36. PubMed ID: 20135094
    [Abstract] [Full Text] [Related]

  • 3. Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment.
    Ma YL, Zeng QQ, Chiang AY, Burr D, Li J, Dobnig H, Fahrleitner-Pammer A, Michalská D, Marin F, Pavo I, Stepan JJ.
    Bone; 2014 Feb; 59():139-47. PubMed ID: 24269280
    [Abstract] [Full Text] [Related]

  • 4. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 5. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
    Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
    [Abstract] [Full Text] [Related]

  • 6. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.
    J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
    [Abstract] [Full Text] [Related]

  • 7. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
    Borah B, Ritman EL, Dufresne TE, Jorgensen SM, Liu S, Sacha J, Phipps RJ, Turner RT.
    Bone; 2005 Jul; 37(1):1-9. PubMed ID: 15894527
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.
    Kučukalić-Selimović E, Valjevac A, Hadžović-Džuvo A, Skopljak-Beganović A, Alimanovic-Alagić R, Brković A.
    Bosn J Basic Med Sci; 2011 Feb; 11(1):41-5. PubMed ID: 21342141
    [Abstract] [Full Text] [Related]

  • 9. Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties.
    Hassler N, Gamsjaeger S, Hofstetter B, Brozek W, Klaushofer K, Paschalis EP.
    Osteoporos Int; 2015 Jan; 26(1):339-52. PubMed ID: 25315260
    [Abstract] [Full Text] [Related]

  • 10. Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: randomized comparison to alendronate.
    Chavassieux P, Meunier PJ, Roux JP, Portero-Muzy N, Pierre M, Chapurlat R.
    J Bone Miner Res; 2014 Mar; 29(3):618-28. PubMed ID: 23959630
    [Abstract] [Full Text] [Related]

  • 11. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.
    Bone HG, Downs RW, Tucci JR, Harris ST, Weinstein RS, Licata AA, McClung MR, Kimmel DB, Gertz BJ, Hale E, Polvino WJ.
    J Clin Endocrinol Metab; 1997 Jan; 82(1):265-74. PubMed ID: 8989272
    [Abstract] [Full Text] [Related]

  • 12. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [Abstract] [Full Text] [Related]

  • 13. Actions of osteoporosis treatments on bone histomorphometric remodeling: a two-fold principal component analysis.
    Wan X, Zhao Y, Burge R, Jiang Y.
    Osteoporos Int; 2013 Dec; 24(12):3011-9. PubMed ID: 23881284
    [Abstract] [Full Text] [Related]

  • 14. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.
    Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF.
    J Bone Miner Res; 2005 Jul; 20(7):1244-53. PubMed ID: 15940379
    [Abstract] [Full Text] [Related]

  • 15. Modulation of bone turnover by alfacalcidol and/or alendronate does not prevent glucocorticoid-induced osteoporosis in growing minipigs.
    Akahoshi S, Sakai A, Arita S, Ikeda S, Morishita Y, Tsutsumi H, Ito M, Shiraishi A, Nakamura T.
    J Bone Miner Metab; 2005 Jul; 23(5):341-50. PubMed ID: 16133683
    [Abstract] [Full Text] [Related]

  • 16. Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate.
    Allen MR, Turek JJ, Phipps RJ, Burr DB.
    Bone; 2011 Jul; 49(1):128-32. PubMed ID: 20637914
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.
    Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP, Libanati C, Boyce RW, Wang A, Grauer A.
    J Bone Miner Res; 2019 Sep; 34(9):1597-1608. PubMed ID: 31233639
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.